Production (Stage)
Xenon Pharmaceuticals Inc.
XENE
$29.75
-$0.74-2.43%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.50M | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.50M | -- | -- | -- | -- |
| Cost of Revenue | 61.20M | 59.47M | 56.97M | 49.70M | 44.25M |
| Gross Profit | -53.70M | -59.47M | -56.97M | -49.70M | -44.25M |
| SG&A Expenses | 19.04M | 18.01M | 16.71M | 19.40M | 14.79M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 80.24M | 77.48M | 73.68M | 69.10M | 59.04M |
| Operating Income | -72.74M | -77.48M | -73.68M | -69.10M | -59.04M |
| Income Before Tax | -64.62M | -69.53M | -63.11M | -58.26M | -47.52M |
| Income Tax Expenses | 427.00K | -3.85M | -320.00K | -333.00K | 412.00K |
| Earnings from Continuing Operations | -65.05M | -65.69M | -62.79M | -57.92M | -47.93M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -65.05M | -65.69M | -62.79M | -57.92M | -47.93M |
| EBIT | -72.74M | -77.48M | -73.68M | -69.10M | -59.04M |
| EBITDA | -72.08M | -76.84M | -73.01M | -68.45M | -58.46M |
| EPS Basic | -0.83 | -0.84 | -0.81 | -0.75 | -0.62 |
| Normalized Basic EPS | -0.51 | -0.55 | -0.51 | -0.47 | -0.38 |
| EPS Diluted | -0.83 | -0.84 | -0.81 | -0.75 | -0.62 |
| Normalized Diluted EPS | -0.51 | -0.55 | -0.51 | -0.47 | -0.38 |
| Average Basic Shares Outstanding | 78.69M | 78.39M | 77.93M | 77.67M | 77.59M |
| Average Diluted Shares Outstanding | 78.69M | 78.39M | 77.93M | 77.67M | 77.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |